Search the web
Welcome, Guest
[Sign Out, My Account]

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
VRTX > SEC Filings for VRTX > Form 8-K on 22-Nov-2013All Recent SEC Filings

Show all filings for VERTEX PHARMACEUTICALS INC / MA | Request a Trial to NEW EDGAR Online Pro



Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement.

On November 19, 2013, we entered into an amendment to our License, Development, Manufacturing and Commercialization Agreement, effective June 30, 2006, with Janssen Pharmaceutica NV, or Janssen. Pursuant to the amendment:

Janssen will make a payment of $152.0 million to us in the fourth quarter of 2013;

Janssen's obligations to pay us royalties on net sales of INCIVO (telaprevir) will terminate after the fourth quarter of 2013; and

Janssen received a fully-paid license to commercialize INCIVO in its territories, subject to the continued payment of certain third-party royalties on its net sales of INVICO.

  Add VRTX to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for VRTX - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial Sign Up Now

Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.